Company Overview and News

to your dashboard

Headline News

Biotech Forum Daily Digest For January 18th

2018-01-18 seekingalpha
There has been some volatile trading action in the biotech sector this week on fears of a government shutdown and potential M&A action. (145-0)

Your Daily Pharma Scoop: Eiger Selloff, Novartis' Cosentyx, RXi Outlines Business Strategy

2018-01-17 seekingalpha
Today we will discuss the results from the phase 2 LIBERTY Study announced by clinical stage biopharmaceutical company, Eiger Biopharmaceuticals (EIGR). (62-0)

Biotech Analysis Central Pharma News: Merck's Keytruda Rises, Celgene's Possible Next Move, Eiger's Phase 2 Dip

2018-01-17 seekingalpha
Merck gains an edge over Bristol-Myers and Roche after positive phase 3 data in first-line non-small cell lung cancer. (81-0)

After an Implosion, Reviewing Analyst Stocks Called to Rise 100% or More

2018-01-16 247wallst
24/7 Wall St. reviews dozens of analyst research reports each day of the week. This ends up being hundreds of analyst calls over the course of a month, and it ends up being thousands of analyst calls over the course of each year. It’s no secret that there is a raging bull market in stocks now that 2018 is underway, and that’s on the heels of the Dow rising 25% and the S&P 500 gaining over 19% in 2017. (7-0)

Why Eiger BioPharma Shares Are Getting Crushed

2018-01-16 247wallst
Shares of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) cratered on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension (PAH) did not meet its primary endpoint. As a result, the company is discontinuing the development of ubenimex in PAH. (7-0)

Will Intuitive Surgical (ISRG) Disappoint in Q4 Earnings?

2018-01-16 zacks
Intuitive Surgical Inc.’s (ISRG - Free Report) fourth-quarter 2017 results, scheduled for release on Jan 25, are expected to show steady growth in instruments and accessories revenues — one of the major revenue components. While this could majorly drive earnings in the quarter under review, an expected improvement in revenues at all other segments should help the company generate solid results this season. (68-0)

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

Eiger BioPharma abandons blood pressure drug after failed study - Channel NewsAsia

2018-01-16 channelnewsasia
REUTERS: Eiger BioPharmaceuticals Inc said on Tuesday it would stop testing its drug ubenimex for the treatment of pulmonary arterial hypertension, a type of high blood pressure, after the drug failed to meet the main goal in a mid-stage study. (7-0)

3 Pharma and Biotech Stocks to Watch Out for in 2018

2018-01-15 zacks
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE ARCA Pharmaceutical index gaining 18.7% and 11.8%, respectively. Although the industry continued to face headwinds in the form of drug pricing scrutiny, pricing pressure, increasing competition, concerns regarding Amazon’s interest in entering the healthcare arena, fewer-than-expected acquisition deals and major pipeline setbacks, there were some positive developments as well. (94-0)

Stocks To Watch: CES Headlines Blockbuster Conference Slate

2018-01-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (861-8)

30 Big Biotech Events Coming in 2018

2017-12-31 247wallst
Over the past year, biotech companies have more or less kept pace with the markets, but they have the potential to break out in 2018. While they have been the obvious beneficiaries of a raging bull market, there have been plenty of factors that have held biotechs back as well. (285-7)

Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge

2017-12-22 zacks
Eiger BioPharmaceuticals, Inc. (EIGR - Free Report) is a biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on EIGR’s earnings for the coming quarter and year. (7-0)

EIGR / Eiger BioPharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders -

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has 47 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 5,832,729 shares. Largest shareholders include Vivo Capital, LLC, Interwest Venture Management Co, Prosight Management, LP, Sphera Funds Management Ltd., and Sabby Management, Llc. (7-2)

CLDN / Celladon Corporation - Stock Institutional Ownership and Shareholders -

Celladon Corporation (NASDAQ:CLDN) has 1 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,787,091 shares. Largest shareholders include Vivo Ventures VI, LLC. (10-0)

CUSIP: 15117E107